TARA

Protara Therapeutics, Inc. Common Stock

2.30

USD

+0.17

+7.98%

Nov 06, 15:59 UTC -5

Closed

After-Market

2.37

+0.07

+3.22%

Protara Therapeutics, Inc. Common Stock (TARA) Earnings

TARA Earnings Reports

Positive Surprise Ratio

TARA beat 29 of 44 last estimates.

66%

Next Report

Date of Next Report

Mar 08, 2027

Estimate for Q4 26 (Revenue/ EPS)

-$0.37

Implied change from Q3 26 (Revenue/ EPS)

+5.71%

Implied change from Q4 25 (Revenue/ EPS)

Protara Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 06, 2026, TARA reported earnings of -0.35 USD per share (EPS) for Q3 26, beating the estimate of -0.37 USD, resulting in a 6.17% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.98% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.37 USD, with revenue projected to reach -- USD, implying an increase of 5.71% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Aclaris Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.12

Surprise

+28.49%

Minerva Neurosciences, Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.12

Actual

$1.94

Surprise

+1,629.97%

Organogenesis Holdings Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.17

Actual

-$0.25

Surprise

-40.06%

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Dyne Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.92

Actual

-$1.06

Surprise

-15.57%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Aldeyra Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.06

Surprise

+37.43%

Lipocine Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.36

Actual

-$0.08

Surprise

+77.91%

Ernexa Therapeutics Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$3.91

Actual

-$1.89

Surprise

+51.75%

FAQ

What were Protara Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Protara Therapeutics, Inc. Common Stock reported EPS of -$0.35, beating estimates by 6.17%, and revenue of $0.00, 0% as expectations.

How did the market react to Protara Therapeutics, Inc. Common Stock's Q3 2026 earnings?

The stock price moved up 7.98%, changed from $2.13 before the earnings release to $2.30 the day after.

When is Protara Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 08, 2027.

What are the forecasts for Protara Therapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Protara Therapeutics, Inc. Common Stock is expected to report EPS of -$0.37 and revenue of -- for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.